Hope of life beyond CD30+ lymphoma[1*]

Takeda
ONCOLOGY
Takeda Pharmaceuticals (HK) Ltd
P.O. Box 47256
Morrison Hill Post Office Hong Kong
Tel : 2133 9800 Fax : 2856 2728

Abbreviated Prescribing Information (EU-OCT2023 - HK-JAN2024)
ADCETRIS 50 mg powder for concentrate for solution for infusion.
Active Ingredient: Brentuximab vedotin **Indication:** Treatment of adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD); Treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT; Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or at least 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option; In combination with cyclophosphamide, doxorubicin and prednisone (CHP) for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL); Treatment of adult patients with relapsed or refractory sALCL; Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. **Dose & Administration:** Previously untreated HL: In combination with chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]), 1.2mg/kg IV infusion over 30 min on days 1 and 15 of each 28-day cycle for 6 cycles. HL at increased risk of relapse or progression following ASCT & CTCL after at least 1 prior systemic therapy: 1.8 mg/kg IV infusion over 30 min every 3 wk up to max of 16 cycles. Previously untreated sALCL: In combination with chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP]), 1.8 mg/kg IV infusion over 30 minutes every 3 weeks for 6 to 8 cycles. Relapsed or refractory HL & relapsed or refractory sALCL: 1.8mg/kg IV infusion over 30 min every 3 wk, patients who achieve stable disease or better should receive a minimum of 8 cycles and up to a max of 16 cycles. **Contraindications:** Hypersensitivity to brentuximab vedotin or the excipients. Combined use of brentuximab & bleomycin. **Special Population:** Closely monitor for new or worsening neurological, cognitive or behavioural signs or symptoms suggestive of progressive multifocal leukoencephalopathy (PML); new or worsening abdominal pain suggestive of acute pancreatitis; new or worsening pulmonary symptoms; emergence of serious & opportunistic infections; immediate & delayed infusion-related reactions. Discontinue use if anaphylaxis & Stevens-Johnson syndrome occurs. Patient w/rapidly proliferating tumour & high tumour burden at risk of tumour lysis syndrome. Monitor for symptoms of neuropathy. Patient experiencing new or worsening peripheral neuropathy may require delay & dose reduction or discontinuation of treatment. Monitor CBC prior to therapy; serum glucose. Patient w/ an elevated BMI w/ or w/o history of DM; renal & hepatic impairment; on controlled Na-diet. Women of childbearing potential should use 2 methods of contraception during & until 6 months after therapy. Men should not father a child during therapy & for up to 6 mth after last dose. May affect ability to drive or operate machinery. Childn & elderly. **Adverse Reactions:** Infection, sepsis/septic shock, upper resp tract infection, herpes zoster, pneumonia, herpes simplex, oral candidiasis; neutropenia, anaemia, febrile neutropenia, thrombocytopenia; Decreased appetite, hyperglycaemia; peripheral sensory neuropathy, peripheral motor neuropathy, dizziness; cough, dyspnoea; diarrhoea, nausea, vomiting, constipation, abdominal pain, stomatitis; elevation of ALT/AST; alopecia, pruritus, rash; myalgia, arthralgia, back pain, bone pain; fatigue, pyrexia, infusion-related reactions, chills.

For detailed information, please consult full prescribing information.
For reporting suspected side effects for Takeda products at AE.HongKong@takeda.com
For asking medical information and other inquiries for Takeda products at medinfohk@takeda.com

Reference: 1* Adcetris Package Insert, EU-OCT2023 - HK-JAN2024
C-APROM/HK/ ADCE/0054 (10/2025)